Krystal Biotech
Krystal Biotech Inc is an American commercial-stage biotechnology company developing topical and redeliverable gene therapies for rare genetic diseases. The company's proprietary STAR-001 platform utilizes engineered HSV-1 viral vectors to deliver functional genes directly to skin and tissue cells. Its FDA-approved flagship product, Vyjuvek, is a topical gene therapy designed to treat dystrophic epidermolysis bullosa by restoring functional type VII collagen. Principal revenue is derived from direct commercial sales of Vyjuvek in North America, alongside government research grants and licensing agreements for international drug commercialization. Krystal Biotech holds a pioneering commercial position as the first company to gain regulatory approval for a topical redeliverable gene therapy. Headquartered in Pittsburgh, Pennsylvania, the company's common stock is publicly listed and traded on the Nasdaq Global Market under the ticker KRYS.
9 of the funds FundTelligence covers report a position in Krystal Biotech.
- Legal name
- Krystal Biotech Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 9
- Exposure themes
- Gene Therapy, Genetic Medicine, Precision Medicine & Genomics
Funds holding Krystal Biotech
- HealthInvest Small & Mid Cap Healthcare — HealthInvest · 4.7 % (partially disclosed portfolio, September 2026)
- Handelsbanken Helse Tema — Handelsbanken · 0.81 % (full portfolio disclosed, October 2026)
- SEB Läkemedelsfond — SEB · 0.78 % (full portfolio disclosed, June 2026)
- Handelsbanken Amerika SMB Tema — Handelsbanken · 0.74 % (full portfolio disclosed, October 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.57 % (full portfolio disclosed, October 2026)
- Franklin Biotechnology Discovery Fund — Franklin Templeton · 0.44 % (full portfolio disclosed, September 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.09 % (full portfolio disclosed, October 2026)
- DNB Global Enhanced Small Cap — DNB · 0.08 % (full portfolio disclosed, September 2026)
Showing the 8 largest of 9 funds holding it.